Intra-arterial Tenecteplase for Acute Medium Vessel Occlusion Stroke

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 488 participants.

Also called NCT07357987

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 488 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07357987
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07357987. Randomized; single masking; primary purpose treatment. Start 2026-01-22 (actual); primary completion 2027-09-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Intra-arterial Tenecteplase for Acute Medium Vessel Occlusion Stroke
Acronym
ANGEL-MeVO-TNK
Condition
Medium Vessel Occlusion
Condition
Tenecteplase
Condition
Endovascular Treatment
Intervention (Procedure)
Intra-arterial Tenecteplase
Intervention (Drug)
standard medical management
Lead sponsor
Beijing Tiantan Hospital (class: other)
Collaborator
Boehringer Ingelheim (class: industry)

Record details

Record id
cardio:ct-nct07357987
Content hash
dae3f0d7a0bc5b91707088f59ee9e3cca7c9d02d7ab3580f2e785112c86eec25